Results 81 to 90 of about 160,542 (279)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer

, 2020
BACKGROUND:Inhibition of the programmed cell death protein 1 (PD-1) pathway has demonstrated clinical benefit in metastatic urothelial cancer (mUC); however, response rates of 15% to 26% highlight the need for more effective therapies.
Shore, Neal, Tian Zhang, Alva, Ajjai S, Daniel J. George, Janet Staats, Munugalavadla, Veerendra, Raquel Izumi, O'Donnell, Peter H, Zhang, Tian, Cetnar, Jeremy, Ajjai S. Alva, Schmidt, Emmett V, Leonard J. Appleman, Appleman, Leonard J, Burke, John M, Guru P. Sonpavde, John M. Burke, Veerendra Munugalavadla, Milowsky, Matthew I, Matthew I. Milowsky, Weinhold, Kent J, Staats, Janet, Neal Shore, Fleming, Mark T, Priti Patel, Mark T. Fleming, Patel, Priti, Harrison, Michael R, Mortazavi, Amir, Sonpavde, Guru P, Jeremy Cetnar, Bojena Bitman, Amir Mortazavi, Cliburn Chan, Noah M. Hahn, Hahn, Noah M, Bitman, Bojena, Michael R. Harrison, Emmett V. Schmidt, Izumi, Raquel, Peter H. O'Donnell, Kent J. Weinhold, Chan, Cliburn, George, Daniel J   +43 more
core   +1 more source

Humanized immune system animal models and their recent applications

Animal Models and Experimental Medicine, EarlyView.
In this review, we provide an updated and comprehensive overview of the current state of humanized immune system animal model research. We discuss the variety of techniques used to produce humanized mice with their respective strengths and weaknesses, and evaluate the advantages and limitations of these models, including issues with incomplete immune ...
Nicolas Skuli, Rudra B. Amin, A’ishah Bakayoko, Marisa Kruidenier, Sahara Aqui, Sarah J. Skuli, Terence P. Gade   +6 more
wiley   +1 more source

Pembrolizumab-induced asthma exacerbation with hypereosinophilia and elevated interleukin-5 in endometrial cancer: A case report

Respiratory Medicine Case Reports
Pembrolizumab is an anti-programmed cell death-1 (PD-1) antibody used to treat various cancer types. Treatments with such immune checkpoint inhibitors cause immune-related adverse events.
Tomoya Harada, Naoki Uetani, Genki Inui, Hiroki Ishikawa, Yoshihiro Funaki, Miki Takata, Ryota Okazaki, Kosuke Yamaguchi, Masato Morita, Shin Kitatani, Akira Yamasaki   +10 more
doaj   +1 more source

Gephyrin Neurological Autoimmunity

Annals of Neurology, EarlyView.
Gephyrin is a postsynaptic scaffold protein essential for inhibitory neurotransmission. Gephyrin‐immunoglobulin G (IgG) was reported, decades ago, in a single case of paraneoplastic stiff‐person‐like syndrome, but its broader clinical relevance remains unknown.
Maria Chiara Pantuliano, Friederike A. Arlt, Naomi Arenson, Irena Dujmovic Basuroski, Divyanshu Dubey, Connie E. Lesnick, John R. Mills, Sean J. Pittock, Anastasia Zekeridou, Michael A. Lane, Andrew McKeon   +10 more
wiley   +1 more source

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

, 2017
Ashwin Somasundaram, Timothy F Burns Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA Abstract: Lung cancer is the leading killer of both men and women in the US, and the 5-year ...
Somasundaram A, Burns TF
core  

Pembrolizumab Systematic Review

A systematic review of clinical trials investigating pembrolizumab monotherapy in GI cancer patients to assess the spectrum and incidence of immune-related adverse events (irAEs) associated with ...
Sakti Chakrabarti, Nikolas Naleid
core   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma

, 2019
Junichi Inokuchi, Masatoshi EtoDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanAbstract: The prognosis of patients with unresectable or metastatic urothelial carcinoma (UC) is poor. Platinum-based chemotherapy
Inokuchi J, Eto M
core  

Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies.

, 2020
Pembrolizumab is an immune checkpoint inhibitor (programmed cell death 1) approved for use in non-small cell lung carcinoma (NSCLC). Pembrolizumab has shown remarkable results in regression of the size of tumors in NSCLC and has shown survival advantage.
Chaudry, Abdul, Chaudry, Misbat, MD, Aslam, Jonaid, MD   +2 more
core  

Pembrolizumab Versus High-Dose Interferon-α2b as Adjuvant Therapy for Pediatric Melanoma: A Retrospective Study

Dermatology Practical & Conceptual
Introduction: Pembrolizumab is well-tolerated in pediatric patients with advanced tumors, consistent with results in adults. However, information on the safety and efficacy of adjuvant pembrolizumab in children and adolescents with melanoma is lacking.
Yu Du, Zhonghui Qi, Xianbin Liang , Jie Dai, Xiaoting Wei , Xue Bai , Lili Mao, Zhihong Chi , Chuanliang Cui, Bin Lian, Bixia Tang , Xuan Wang , Yu Chen , Jun Guo , Lu Si   +14 more
doaj   +1 more source